Advanced Kidney Disease: Care and Monitoring

Advanced kidney disease is where the complexity of chronic kidney disease reaches its peak. At Stages G4 (eGFR 15–29) and G5 (eGFR below 15), the kidneys are severely to critically impaired, complications become clinically prominent across multiple organ systems, and the decisions that determine what happens next — whether dialysis, a transplant, or conservative care — become pressing. Managing advanced kidney disease is not a single intervention; it is an ongoing coordination of monitoring, complication management, medication review, symptom treatment, and preparation for the transition to kidney replacement therapy. Patients who understand what advanced CKD involves, what to monitor, and how to prepare are far better positioned to navigate this stage without being caught off guard by a preventable crisis.

Understanding Stages G4 and G5

The KDIGO classification system uses eGFR to stage CKD from G1 through G5. Stages G4 and G5 together constitute advanced kidney disease — the stages in which kidney function has declined to a level where the body’s compensatory mechanisms are increasingly overwhelmed and external medical support (or kidney replacement therapy) becomes necessary.

Stage G4 is defined by an eGFR between 15 and 29 ml/min/1.73m² — a severe reduction. The kidneys are performing at roughly 15 to 30 percent of normal capacity. At G4, complications that were manageable at earlier stages intensify: anemia becomes harder to control, electrolyte imbalances require more active intervention, bone disease worsens, and the first uremic symptoms — nausea, fatigue, difficulty concentrating — begin to emerge. For many patients, G4 is the stage at which kidney disease transitions from a condition monitored at routine appointments to one that drives significant daily life management. Crucially, G4 is also the stage at which preparation for kidney replacement therapy must begin — not as an abstract future concern, but as an active, time-sensitive clinical process.

Stage G5 is kidney failure: an eGFR below 15 ml/min/1.73m². At this level, the kidneys can no longer maintain the body’s internal environment without assistance. The full spectrum of uremic symptoms is present, and kidney replacement therapy — hemodialysis, peritoneal dialysis, or kidney transplant — is required for survival unless the patient has chosen conservative kidney management. The rate at which an individual progresses from G4 to G5 is highly variable. Some patients remain at G4 for years with well-managed disease; others decline within months. This variability makes the preparation work started at G4 all the more important — the window for unhurried planning may be shorter than expected. A comprehensive overview of how each CKD stage differs is provided in our guide to chronic kidney disease stages explained.

Symptoms at Advanced Kidney Disease

Advanced CKD affects nearly every organ system. Understanding the symptom landscape helps patients recognize what is caused by their kidney disease, communicate effectively with their care team, and identify which symptoms require same-day attention versus routine management.

Fatigue is one of the most consistently debilitating symptoms at G4 and G5. Its primary driver is anemia — the kidneys produce erythropoietin, the hormone that signals red blood cell production, and at advanced stages this capacity is severely diminished. Hemoglobin levels commonly fall to 7–10 g/dL without erythropoiesis-stimulating agent (ESA) therapy. Even with ESAs and IV iron, achieving the target hemoglobin of 10–11.5 g/dL can be challenging, particularly as disease progresses.

Nausea, vomiting, appetite loss, and metallic taste represent the gastrointestinal manifestations of uremia — the accumulation of waste products the kidneys no longer excrete. Urea is converted by intestinal bacteria into ammonia, contributing to the distinctive metallic taste that many G4–G5 patients describe. Anorexia (loss of appetite) combined with the metabolic catabolism of advanced CKD leads to progressive muscle wasting and weight loss. A renal dietitian is essential at this stage to maintain adequate nutritional intake while managing the electrolyte restrictions that complicate eating choices.

Fluid overload and edema occur because the kidneys can no longer excrete the fluid and sodium consumed each day. Peripheral edema — swelling in the legs and ankles — is common; in advanced cases, fluid accumulates in the abdomen and lungs. Weight gain of more than two kilograms over a few days typically represents fluid retention, not fat gain, and should be reported to the care team. High-dose loop diuretics (furosemide at 80 to 160 mg or more per day) are used to maintain fluid balance, but their efficacy progressively diminishes as kidney function falls.

Restless legs syndrome — the irresistible urge to move the legs, especially at night — affects a substantial proportion of advanced CKD patients and worsens as eGFR declines. It is frequently one of the most quality-of-life-impairing symptoms and is often underreported because patients do not think of it as a kidney disease complication. It should be raised at every advanced CKD appointment.

Uremic pruritus — severe itching — affects 40 to 70 percent of patients at Stage G5 and is significant at G4. Its mechanism involves κ-opioid receptor activation by uremic toxins. Difelikefalin (FDA-approved 2021 for dialysis-associated pruritus), nalbuphine ER, and gabapentin are treatment options.

Emergency symptoms that require same-day contact with the nephrology team include chest pain that worsens lying flat (uremic pericarditis), new-onset or worsening confusion or inability to think clearly (uremic encephalopathy), inability to catch one’s breath at rest, and severe muscle weakness or irregular heartbeat (hyperkalemia). These represent situations where urgent or emergent dialysis initiation may be required.

The Complications That Require Active Management

Advanced CKD produces a predictable cluster of complications — each of which requires active treatment, not watchful waiting. The key distinction from earlier CKD stages is the intensity of management required and the degree to which these complications interact with each other and with treatment choices.

Anemia at G4–G5 is managed with erythropoiesis-stimulating agents (darbepoetin alfa or epoetin alfa) plus intravenous iron supplementation. Oral iron is poorly absorbed in advanced CKD; IV iron (ferric carboxymaltose, iron sucrose, or low-molecular-weight iron dextran) is the standard. The hemoglobin target is 10 to 11.5 g/dL — adequate to relieve symptoms without the elevated cardiovascular risks associated with higher targets. Iron stores (transferrin saturation and ferritin) are monitored at every iron-supplementation visit.

Metabolic acidosis worsens at G4 as the kidneys’ ability to excrete acid and regenerate bicarbonate is severely diminished. Oral sodium bicarbonate supplementation is used to maintain serum bicarbonate above 22 mEq/L. Untreated acidosis accelerates muscle protein catabolism, worsens bone disease, and contributes to malnutrition — all significant complications at advanced CKD stages.

Hyperkalemia (elevated blood potassium) is a constant management challenge at G4–G5 because the kidneys are the primary route of potassium excretion. Dietary potassium restriction (typically 2 grams per day or below) is combined with potassium-binding agents — patiromer (Veltassa) or sodium zirconium cyclosilicate (Lokelma) — taken daily. A key principle: potassium binders allow patients to remain on ACE inhibitors and ARBs, which provide kidney and cardiovascular protection, without being stopped due to hyperkalemia. This is the preferred strategy over discontinuing RAAS agents.

Secondary hyperparathyroidism and CKD-mineral and bone disorder (CKD-MBD) requires a three-pronged approach at advanced stages: phosphate binders (taken with meals to bind dietary phosphate in the gut), active vitamin D analogs (calcitriol or paricalcitol, to suppress PTH and improve calcium absorption), and cinacalcet (a calcimimetic that reduces PTH secretion by sensitizing the parathyroid gland to calcium). Uncontrolled CKD-MBD causes bone disease, vascular calcification, and significantly elevated cardiovascular risk.

Fluid overload management combines pharmacological and dietary approaches. High-dose furosemide (80 to 320 mg daily), combined with strict sodium restriction (under 2 grams per day) and fluid restriction, maintains volume balance for as long as kidneys retain some diuretic responsiveness. When diuretics become ineffective — fluid is retained despite maximum doses — this becomes an indication for starting dialysis for fluid management.

Protein-energy wasting (PEW) — the combination of muscle wasting, low albumin, and inadequate caloric intake — is a major risk at G4–G5 and an independent predictor of mortality. Managing it requires the collaboration of a renal dietitian who can navigate the competing demands of adequate caloric and protein intake, phosphate restriction, potassium restriction, and sodium restriction simultaneously.

Monitoring at Stages G4 and G5

Monitoring intensity increases substantially at advanced CKD stages to match the growing number and severity of complications. At Stage G4, laboratory monitoring should occur every one to three months; at G5, every one to two months, or more frequently if instability in any parameter warrants closer surveillance.

The core laboratory panel at each G4–G5 monitoring visit includes: serum creatinine and eGFR (trajectory tracking), complete blood count (hemoglobin, monitoring ESA response), electrolytes (potassium, sodium, chloride), serum bicarbonate (acidosis management), urine albumin-to-creatinine ratio (continued proteinuria monitoring), phosphate, corrected calcium, parathyroid hormone (PTH), ferritin and transferrin saturation (iron stores for ESA management), and lipid panel at appropriate intervals. Blood pressure is measured at every visit, and patient weight is assessed at every visit to evaluate volume status.

Nutritional assessment — by the renal dietitian — occurs every one to three months at G4 and monthly at G5. Malnutrition at advanced CKD is a strong predictor of poor outcomes on dialysis and post-transplant, making this assessment critical. Dietitian visits at this stage are not optional extras; they are a core component of the care plan. The full list of what is monitored at each CKD stage and how each parameter should be interpreted is in our annual kidney health checklist.

After dialysis begins, the monitoring framework shifts. Dialysis adequacy (measured by Kt/V — a calculation of urea clearance relative to body volume) is assessed monthly for hemodialysis patients. For peritoneal dialysis patients, a peritoneal equilibration test (PET) is conducted periodically to assess the efficiency of the peritoneal membrane as a filter. Lab panels at G5D (dialysis-dependent Stage 5) are performed before each dialysis session for electrolytes and after sessions periodically for adequacy assessments.

Preparing for Kidney Replacement Therapy at Stage G4

The most consequential work at Stage G4 is not symptom management — it is preparation for kidney replacement therapy. Patients who begin this preparation at G4, while there is still time for unhurried decision-making and proper medical lead times, have dramatically better outcomes at the time of transition than patients whose KRT preparation begins only when crisis arrives.

The preparation pathway depends on the chosen modality. For hemodialysis, vascular access creation is the critical step. An arteriovenous (AV) fistula — the preferred access type because of its lower infection and complication rate — requires surgical creation of an artery-to-vein connection, followed by three to six months of maturation time before it can be used reliably for dialysis. Patients who begin dialysis without a mature fistula — relying on a tunneled central venous catheter — face significantly higher rates of bloodstream infection, hospitalization, and mortality. The clinical implication is direct: AV fistula referral should occur at Stage G4, when the maturation timeline allows for a working fistula by the time dialysis is needed. Detailed information about what patients face at the stage immediately before this transition is in our guide to Stage 4 kidney disease: what to expect.

For peritoneal dialysis, a PD catheter is placed surgically or laparoscopically, with a healing period of approximately two to four weeks before use. This shorter lead time than hemodialysis access makes PD planning more flexible, but training in home exchange technique still takes one to two weeks after catheter healing. PD is worth exploring early because many patients who would prefer home-based therapy are steered toward in-center hemodialysis simply because PD was never presented as an option during the G4 planning window.

For transplant, the preparation timelines are the longest and most front-loaded. Deceased-donor waitlist registration is possible when eGFR falls to 20 or below, and time on the waitlist accrues from registration — not from dialysis start. Complete transplant evaluation (cardiac testing, infectious disease and cancer screening, psychosocial evaluation) can take several months. Living-donor evaluation for a potential family member or friend takes three to six months. Patients interested in a living-donor transplant — which offers the best long-term outcomes of all KRT options — must begin the conversation with their transplant center and potential donors as early in the G4 stage as possible. A specific perspective on what Stage 5 patients face when KRT decisions must be finalized is in our companion article on Stage 5 kidney disease: what patients should know.

Medications to Continue and Medications to Avoid

Medication management at G4–G5 is one of the most complex aspects of advanced CKD care. Multiple agents need dose adjustment, some must be avoided entirely, and the interactions between kidney disease, the medications used to treat it, and the medications used for other health conditions require active pharmacological review at every appointment.

ACE inhibitors and ARBs should generally be continued at G4–G5 unless significant side effects or extreme eGFR instability develop. They provide continued kidney and cardiovascular protection even at low eGFR values, and the hyperkalemia concern they create is managed with potassium binders rather than by stopping the RAAS agent. During acute illness with vomiting, diarrhea, or fever, these medications may need to be temporarily held — a sick-day protocol should be established with the provider.

SGLT2 inhibitors have diminishing glycemic efficacy as eGFR falls below 30, but they retain cardiovascular benefits at G4 eGFR levels for patients with heart failure or established cardiovascular disease. KDIGO 2024 guidance supports their continuation at G4 for cardiovascular benefit when the indication is heart failure or CKD with cardiovascular disease.

NSAIDs (ibuprofen, naproxen, celecoxib) are absolutely contraindicated at G4 and G5. They block prostaglandin-mediated afferent arteriolar vasodilation — causing renal vasoconstriction that can produce acute kidney injury on top of advanced CKD, sometimes precipitating a crisis that accelerates dialysis need. This applies to over-the-counter as well as prescription formulations. Acetaminophen is the safe alternative for most pain management needs.

Metformin should be discontinued at eGFR below 30 due to the risk of lactic acidosis from drug accumulation. Alternative glucose-lowering agents — insulin, GLP-1 receptor agonists, or sulfonylureas at reduced doses — are used instead. Many common antibiotics, antivirals, antifungals, anxiolytics, and pain medications require dose reduction at G4–G5; an up-to-date medication review at every nephrology appointment is not optional, it is essential. Gadolinium contrast agents for MRI are contraindicated at G4–G5 due to the risk of nephrogenic systemic fibrosis. Iodinated IV contrast for CT scans requires pre-hydration and post-procedure monitoring of kidney function.

The Multidisciplinary Team at Advanced CKD

Managing advanced kidney disease is not a task for a single provider. The complexity of symptoms, complications, medication management, nutritional needs, and psychosocial demands at G4–G5 exceeds what any one clinician can address within a standard appointment. A functioning multidisciplinary team is not a luxury — it is a prerequisite for good outcomes at this stage.

The nephrologist coordinates overall disease management and drives KRT planning. The renal dietitian is essential from G4 onward — managing the competing dietary restrictions for potassium, phosphate, sodium, protein, and fluid while maintaining adequate nutrition is a specialist skill that requires regular patient contact. The social worker addresses the logistical and emotional dimensions of advanced CKD: insurance coverage for dialysis supplies, transportation to in-center dialysis three times weekly, caregiver support planning, advance directive completion, and the financial stress that advanced illness frequently creates.

A palliative care team member is increasingly included in advanced CKD programs — not as a signal that the patient is dying, but because palliative care specializes in symptom burden management, quality-of-life assessment, advance care planning, and shared decision-making, all of which are directly relevant at G4 and G5 regardless of which KRT path the patient chooses. The primary care physician remains essential for cardiovascular risk management, vaccination, infection treatment, and the broad-spectrum medical management that kidney disease does not replace.

Conservative Kidney Management as a Valid Option

For a subset of patients at advanced CKD — particularly older individuals with significant additional health conditions such as severe heart failure, advanced dementia, or active malignancy — the burden of dialysis may outweigh its benefits. Conservative kidney management (CKM) is an active, structured care approach that focuses on symptom control and quality of life without pursuing dialysis or transplant.

CKM is not the absence of treatment. It includes active management of all symptoms: ESA therapy for anemia, diuretics for fluid overload, phosphate binders, pruritus treatment, pain management, and nutritional support. What it does not include is kidney replacement therapy. The rationale is that for frail patients with limited life expectancy due to non-kidney comorbidities, dialysis imposes a significant burden — three to four hours of treatment three times per week with associated vascular access complications, dietary restriction, and fatigue — without meaningfully extending life or improving its quality. Palliative care and eventually hospice are integrated into the CKM plan.

Conservative kidney management is a valid, legitimate choice that deserves the same clear, unbiased presentation to patients as any other KRT option. Patients choosing CKM benefit from early palliative care involvement, completion of advance directives, and caregiver support planning. Survival without dialysis at G5 ranges from weeks to more than a year depending on residual kidney function and comorbidities. Many patients choosing CKM find that their quality of life remains meaningfully intact longer than they expected.

Questions to Prioritize at Advanced CKD Appointments

Advanced CKD appointments carry significant clinical weight and benefit from patient preparation. The most productive appointments are those where specific, targeted questions are brought rather than a general check-in. At G4 and G5, the questions worth prioritizing include:

• What is my current eGFR compared to six months ago, and how fast is it declining?
• Should I have AV fistula surgery scheduled now, and with which vascular surgeon?
• Am I listed on the transplant waitlist, or is there a reason I should not be?
• Has my potassium been in range, and am I on the right potassium binder dose?
• Are all my current medications at appropriate doses for my current eGFR?
• What symptoms should prompt me to call today rather than waiting for my next appointment?
• Would I benefit from a palliative care consultation to discuss options and preferences?

Arriving with these questions prepared consistently produces more thorough conversations and more actionable care plans. The complete framework for what to ask across all CKD stages is available in our guide on questions to ask during a kidney checkup.

Navigating Advanced CKD With Preparation and Support

Advanced kidney disease demands more from patients — more monitoring appointments, more medications, more dietary discipline, more planning — than any earlier stage of CKD. But it is also the stage that most rewards preparation and engagement. The patients who navigate G4 and G5 with the best outcomes share a common pattern: they understand their lab values and what changes in those values mean, they complete access or transplant preparation before crisis forces a rushed decision, they build and use a multidisciplinary care team, and they have explicit conversations with their providers about what constitutes an emergency and what the plan is if they choose conservative management.

The clinical resources that support this preparation include the NIDDK’s advanced CKD and kidney failure resources, the KDIGO CKD Evaluation and Management Guidelines, and the National Kidney Foundation’s patient education resources. The specific decision framework for what to prepare at the stage immediately before dialysis becomes necessary is in our detailed guide on stage 4 kidney disease: what to expect. Advanced kidney disease is serious, but the window for meaningful preparation and decision-making remains open through Stage G4 — and using that window is the single most important thing a patient can do for their long-term outcome.

Sources: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); KDIGO 2024 CKD Evaluation and Management Guidelines; National Kidney Foundation; American Kidney Fund; Cooper BA et al., IDEAL Trial, NEJM 2010.